Literature DB >> 21878898

Diabetes: type 1 diabetes mellitus--a door opening to a real therapy?

Lucienne Chatenoud.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21878898     DOI： 10.1038/nrendo.2011.148

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

Authors:  Kevan C Herold; William Hagopian; Julie A Auger; Ena Poumian-Ruiz; Lesley Taylor; David Donaldson; Stephen E Gitelman; David M Harlan; Danlin Xu; Robert A Zivin; Jeffrey A Bluestone
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

2.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.

Authors:  B Bielekova; B Goodwin; N Richert; I Cortese; T Kondo; G Afshar; B Gran; J Eaton; J Antel; J A Frank; H F McFarland; R Martin
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

3.  Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Authors: 
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

4.  Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

Authors:  Diane K Wherrett; Brian Bundy; Dorothy J Becker; Linda A DiMeglio; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Carla J Greenbaum; Kevan C Herold; Jennifer B Marks; Roshanak Monzavi; Antoinette Moran; Tihamer Orban; Jerry P Palmer; Philip Raskin; Henry Rodriguez; Desmond Schatz; Darrell M Wilson; Jeffrey P Krischer; Jay S Skyler
Journal:  Lancet       Date:  2011-06-27       Impact factor: 79.321

5.  Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Authors:  Tihamer Orban; Brian Bundy; Dorothy J Becker; Linda A DiMeglio; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Carla J Greenbaum; Jennifer B Marks; Roshanak Monzavi; Antoinette Moran; Philip Raskin; Henry Rodriguez; William E Russell; Desmond Schatz; Diane Wherrett; Darrell M Wilson; Jeffrey P Krischer; Jay S Skyler
Journal:  Lancet       Date:  2011-06-28       Impact factor: 79.321

6.  Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Authors:  Nicole Sherry; William Hagopian; Johnny Ludvigsson; Sunil M Jain; Jack Wahlen; Robert J Ferry; Bruce Bode; Stephen Aronoff; Christopher Holland; David Carlin; Karen L King; Ronald L Wilder; Stanley Pillemer; Ezio Bonvini; Syd Johnson; Kathryn E Stein; Scott Koenig; Kevan C Herold; Anastasia G Daifotis
Journal:  Lancet       Date:  2011-06-28       Impact factor: 79.321

7.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Authors:  Bart Keymeulen; Evy Vandemeulebroucke; Anette G Ziegler; Chantal Mathieu; Leonard Kaufman; Geoff Hale; Frans Gorus; Michel Goldman; Markus Walter; Sophie Candon; Liliane Schandene; Laurent Crenier; Christophe De Block; Jean-Marie Seigneurin; Pieter De Pauw; Denis Pierard; Ilse Weets; Peppy Rebello; Pru Bird; Eleanor Berrie; Mark Frewin; Herman Waldmann; Jean-François Bach; Daniel Pipeleers; Lucienne Chatenoud
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

8.  Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.

Authors:  Mark D Pescovitz; Carla J Greenbaum; Heidi Krause-Steinrauf; Dorothy J Becker; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Jennifer B Marks; Paula F McGee; Antoinette M Moran; Philip Raskin; Henry Rodriguez; Desmond A Schatz; Diane Wherrett; Darrell M Wilson; John M Lachin; Jay S Skyler
Journal:  N Engl J Med       Date:  2009-11-26       Impact factor: 91.245

9.  GAD treatment and insulin secretion in recent-onset type 1 diabetes.

Authors:  Johnny Ludvigsson; Maria Faresjö; Maria Hjorth; Stina Axelsson; Mikael Chéramy; Mikael Pihl; Outi Vaarala; Gun Forsander; Sten Ivarsson; Calle Johansson; Agne Lindh; Nils-Osten Nilsson; Jan Aman; Eva Ortqvist; Peter Zerhouni; Rosaura Casas
Journal:  N Engl J Med       Date:  2008-10-08       Impact factor: 91.245

10.  Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

Authors:  G Feutren; L Papoz; R Assan; B Vialettes; G Karsenty; P Vexiau; H Du Rostu; M Rodier; J Sirmai; A Lallemand
Journal:  Lancet       Date:  1986-07-19       Impact factor: 79.321
  10 in total
  3 in total

1.  Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients.

Authors:  F K Gorus; E V Balti; I Vermeulen; S Demeester; A Van Dalem; O Costa; H Dorchy; S Tenoutasse; T Mouraux; C De Block; P Gillard; K Decochez; J M Wenzlau; J C Hutton; D G Pipeleers; I Weets
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

2.  Real-time immune cell interactions in target tissue during autoimmune-induced damage and graft tolerance.

Authors:  Jason Miska; Midhat H Abdulreda; Priyadharshini Devarajan; Jen Bon Lui; Jun Suzuki; Antonello Pileggi; Per-Olof Berggren; Zhibin Chen
Journal:  J Exp Med       Date:  2014-02-24       Impact factor: 14.307

3.  Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells.

Authors:  R Goto; S You; M Zaitsu; L Chatenoud; K J Wood
Journal:  Am J Transplant       Date:  2013-06-10       Impact factor: 8.086
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.